Fatty Liver Disease: Symptoms, Stages & Treatment

Fatty liver disease occurs when excess fat accumulates in liver cells. It's one of the most common liver conditions in India today, and unlike many chronic diseases, it frequently causes no symptoms at all until it's already fairly advanced — which is exactly why understanding your own risk matters, rather than waiting to feel unwell. Fatty liver exists on a spectrum: at one end, simple fat accumulation that causes no lasting harm; at the other, a more aggressive inflammatory form that can progress over years toward scarring (fibrosis) and, eventually, cirrhosis. At KAGE, fatty liver disease is properly staged — not just diagnosed — using FibroScan and targeted testing, so that treatment matches exactly where a patient sits on that spectrum rather than treating every case the same way.

Population studies in India have reported NAFLD prevalence ranging widely, from around 9% in some rural community studies to over 50% in urban cohorts, with a pooled estimate across studies suggesting roughly one in three Indian adults are affected. The rate is meaningfully higher in cities than in rural areas — one large north Indian study found 53.7% prevalence in urban communities compared to 30.2% in rural ones — and climbs further in people who already have type 2 diabetes or obesity, with some studies reporting more than half of diabetic patients affected. This isn't a rare or unusual finding on a scan; for a large share of urban Indian adults, particularly those with any metabolic risk factor, it's closer to the norm than the exception, which is exactly why proactive screening matters more than waiting for symptoms.

One of the more clinically important, and less well-known, facts about fatty liver disease in Indian and other South Asian populations is that it doesn't only affect people who are overweight. A genetic variant in the PNPLA3 gene, along with a general tendency toward higher visceral (internal abdominal) fat at a given body weight, means South Asians can develop clinically significant fatty liver disease at a normal BMI — a pattern researchers call ‘lean NAFLD.’ In one Indian cohort, roughly a third of lean adults studied were found to have NAFLD. This matters practically: being a healthy weight reduces risk but doesn't eliminate it, and a normal BMI should not rule out fatty liver disease as a possibility if other risk factors or symptoms are present.

• NAFLD (Non-Alcoholic Fatty Liver Disease) — fat accumulation in the liver without significant inflammation or damage; the most common and mildest form
• NASH (Non-Alcoholic Steatohepatitis) — fat accumulation plus inflammation and liver cell damage, which carries a real risk of progressing to fibrosis and cirrhosis over time
• AFLD (Alcohol-related Fatty Liver Disease) — caused by alcohol use rather than metabolic factors, though the liver changes can look similar on imaging

Increasingly, clinicians use the term MASLD (Metabolic dysfunction-Associated Steatotic Liver Disease) in place of NAFLD, reflecting a shift toward defining the disease by its metabolic drivers rather than by ruling out alcohol — you may see both terms used interchangeably.

What actually determines long-term risk isn't whether someone has ‘fatty liver’ as a yes/no label — it's how much fibrosis (scarring) has developed. Fibrosis is staged F0 through F4:

FibroScan is the key non-invasive tool used to determine this stage, which is why staging — not just diagnosing — is central to how fatty liver disease should be managed.

Fatty liver is often called a silent disease, and for good reason: most people with even significant fat accumulation feel completely normal. This is precisely why it's so often discovered incidentally — on an ultrasound done for something else, or a mildly abnormal liver enzyme on a routine blood test.

• Often no symptoms at all, especially in earlier stages
• Fatigue
• Mild discomfort or a dull ache in the upper right abdomen
• In advanced disease: jaundice, swelling in the legs or abdomen, easy bruising — these signal significant liver damage, not early fatty liver, and need urgent evaluation (see below)

• Obesity, particularly abdominal (visceral) obesity
• Type 2 diabetes or insulin resistance — among the strongest risk factors identified in Indian studies
• High cholesterol or triglycerides, and metabolic syndrome more broadly
• A genetic predisposition (such as the PNPLA3 variant), which can cause fatty liver even at a normal weight — see ‘lean NAFLD’ above
• Age over 40, and urban residence, both associated with higher prevalence in Indian studies
• Rapid weight loss, in some cases
• Certain medications
• Regular alcohol use (for the alcohol-related form specifically)

• Blood tests — liver enzymes (ALT, AST) as an initial indicator, though these can be normal even with significant fat present
• Ultrasound — can detect fat accumulation in the liver, though it can't reliably measure fibrosis stage on its own
• FibroScan (transient elastography) — a quick, non-invasive test that measures liver stiffness in kilopascals (kPa) to estimate fibrosis stage; this is the key test for knowing where a patient actually sits on the F0–F4 spectrum
• Liver biopsy — occasionally needed for a definitive diagnosis or precise staging in more complex or uncertain cases

For most people, particularly those with a family history, diabetes, or other metabolic risk factors, meaningful prevention is possible: maintaining a healthy weight, staying physically active, managing blood sugar and cholesterol, and limiting alcohol all measurably reduce risk. Given the lean NAFLD pattern in South Asians, prevention isn't only relevant to people who are overweight — metabolic health markers (blood sugar, cholesterol, waist circumference) matter regardless of BMI. For those already diagnosed, the same measures form the foundation of treatment, not just prevention.

Step 1 — Weight loss and lifestyle change: even a 7–10% reduction in body weight has been shown to meaningfully improve or reverse early fatty liver and NASH; for lean NAFLD patients, the focus shifts more toward metabolic risk factors than weight itself.

Step 2 — Managing associated conditions: better control of diabetes and cholesterol directly improves liver fat, independent of weight change.

Step 3 — Regular monitoring: periodic FibroScan and blood tests to track whether fibrosis is stable, improving, or progressing — the interval depends on the stage found.

Step 4 — Medication: pharmacological options remain limited and are evolving, and are considered case by case, particularly for confirmed NASH with fibrosis.

Step 5 — Specialist liver clinic management for advanced fibrosis (F3–F4) or cirrhosis, including monitoring for complications such as portal hypertension.

Progressive fatty liver disease can advance through worsening fibrosis stages to cirrhosis, with an associated risk of liver failure and hepatocellular carcinoma (liver cancer) in advanced cases. Just as importantly, fatty liver disease is strongly linked to cardiovascular disease — for most patients, the greater long-term health risk is actually heart disease rather than the liver itself, underscoring why fatty liver should prompt a broader look at metabolic health, not just liver-focused treatment.

Fatty liver is common enough to be dismissed, but the question that decides everything is whether fibrosis has begun — answered by FibroScan and blood-based scoring, not by an ultrasound report alone. Our liver specialists run that assessment through the Advanced Liver Care Clinic and, where weight is the driver, alongside obesity treatment. Children are assessed separately for pediatric fatty liver disease. If a scan has reported a fatty liver, book a consultation to find out what stage it is at.